

FORM PTO 1449	ATTY. DOCKET NO. 0249-0001	APPLICATION NO. 09/997,240
INFORMATION DISCLOSURE STATEMENT		
APPLICANT(S) W. Yan		
FILING DATE 11/30/01		GROUP 1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
JW	AA1	5,945,577	8/31/99	Stice, S. et al.			
	AB1	5,843,780	12/1/98	Thomson, J.A.			
	AC1	5,905,042	5/18/99	Stice, S. et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
JW	AD1	WO 01/29206	4/26/01				<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
	AE1	WO 90/03432	4/5/90				<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
	AF1	WO 94/24274	10/27/94				<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
	AG1	WO 94/26889	11/24/94				<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
	AH1	WO 94/26884	11/24/94				<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
	AI1	WO 98/07841	02/26/98				<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

JW	AJ	1	Allen, N. D., et al., "A functional analysis of imprinting in parthenogenetic embryonic stem cells", <i>Development</i> , 120: 1473-82 (1994)
	AK	1	Andrews, P. W., "Teratocarcinomas and human embryology: Pluripotent human EC cells lines", <i>APMIS</i> 106: 158-68 (1998)
	AL	1	Asakura, S. and Abe, S., "Synacrosomal Formation after Cell Fusion of Round Spermatids of <i>Xenopus laevis</i> ", <i>Experimental Cell Research</i> 181: 566-73 (1989)
	AM	1	Assady, S., et al. "Insulin Production by Human Embryonic Stem Cells", <i>Diabetes</i> 50: 1691-97 (2001)
	AN	1	Barriere, P. and Lopes, P., "Fecondation in vitro: stimulation de l'ovulation et recueil des ovocytes", <i>Rev Prat</i> 40(29): 2689-93 (1990)
	AO	1	Borlongan, C.V., et al. "Cerebral ischemia and CNS transplantation: differential effects of grafted fetal rat striatal cells and human neurons derived from a clonal cell line", <i>NeuroReport</i> 9(16): 3703-09 (1998)
	AP	1	Bottero, L., et al., "Differential Activation of Homeobox Genes by Retinoic Acid in Human Embryonal Carcinoma Cells", <i>Recent Results in Cancer Research</i> 123: 133-43 (1991)
	AQ	1	Bradley, A., et al., "Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines", <i>Nature</i> 309: 255-56 (1984)
	AR	1	Brustle, O., et al., "Embryonic Stem Cell-Derived Glial Precursors: A Source of Myelinating Transplants", <i>Science</i> 285: 754-56 (1999)


EXAMINER

Joe W. W. W.

DATE CONSIDERED

6/11/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0249-0001APPLICATION NO.
09/997,240APPLICANT(S)
W. YanFILING DATE
11/30/01

GROUP

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

940	AA	2	Campbell, K. H. S., et al., "Sheep cloned by nuclear transfer from a cultured cell line", <i>Nature</i> 380: 64-66 (1996)
	AB	2	Carritt, B., et al., "Diverse origins of multiple ovarian teratomas in a single individual", <i>P. N.A.S. USA</i> 79:7400-04 (1982)
	AC	2	Cherny, R.A., et al., "Strategies for the Isolation and Characterization of Bovine Embryonic Stem Cells", <i>Reprod. Fertil. Dev.</i> 6:569-75 (1994)
	AD	2	Cho, S. K., et al., "Functional characterization of B lymphocytes generated in vitro from embryonic stem cells", <i>P. N. A. S. USA</i> 96:9797-9802 (1999)
	AE	2	Chomczynski, P. and Sacchi, N., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction", <i>Anal Biochem</i> 162: 156-59 (1987)
	AF	2	Collas, P. and Barnes, F. L., "Nuclear Transplantation by Microinjection of Inner Cell Mass and Granulosa Cell Nuclei", <i>Molecular Reproduction and Development</i> 38: 264-67 (1994)
	AG	2	Dahl, N., et al., "Benign Ovarian Teratomas, An Analysis of Their Cellular Origin", <i>Cancer Genet Cytogenet</i> 46: 115-23 (1990)
	AH	2	Dani, C., "Embryonic Stem Cell-Derived Adipogenesis", <i>Cells Tissues Organs</i> 165: 173-80 (1999)
	AI	2	Dani, C., et al., "Differentiation of embryonic stem cells into adipocytes in vitro", <i>J Cell Sci</i> 110(Pt. 11): 1279-85 (1997)
	AJ	2	Deka, R., et al., "Genetics and Biology of Human Ovarian Teratomas. II. Molecular Analysis of Origin of Nondisjunction and Gene-Centromere Mapping of Chromosome I Markers", <i>Am. J. Hum. Genet.</i> 47: 644-55 (1990)
	AK	2	Doetschman, T., et al., "Establishment of Hamster Blastocyst-Derived Embryonic Stem (ES) Cells", <i>Developmental Biology</i> 127:224-27 (1988)
	AL	2	Doetschman, T.C., et al., "The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium", <i>J. Embryol Exp Morphol</i> 87: 27-45 (1985)
	AM	2	Edwards, B. E., et al., "The Human pluripotent stem cell: impact on medicine and society", <i>Fertility and Sterility</i> 74(1) 1-7 (2000)
	AN	2	Eppig, J. T. and Eicher, E. M., "Application of the Ovarian Teratoma Mapping Method in the Mouse", <i>Genetics</i> 103:797-812 (1983)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

0249-0001

Application Number

09/997,240

Applicant(s)

YAN, et al.

Filing Date

November 20, 2001

Group Art Unit

To Be Determined 1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE



FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
AW	AA	WO01/30978	03.05.2001	WO (PCT)	C12N	5/00		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

Joe L. Fontana

DATE CONSIDERED

6/11/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

0590
0200 #5
4/23

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Yan, et al.

Serial No.: 09/997,240

Filed: November 30, 2001

For: Isolated Homozygous Stem Cells,
Differentiated Cells Derived Therefrom, And
Materials And Methods For Making And
Using Same



Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty. Docket: 0249-0001

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to the Applicants in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the documents are also being submitted herewith. This Supplemental Information Disclosure Statement is a continuation of the Applicant's Information Disclosure Statement filed on February 22, 2002, in connection with the above-captioned application.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application.

This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.


Serial No.: 09/997,240
Atty. Docket No.: 0249-0001

Entry of these references in the record of the prosecution of the above-identified application is respectfully requested.

It is believed that no fees are due for consideration of this Supplemental Information Disclosure Statement. The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0622. A duplicate copy of this Petition is enclosed.


Respectfully submitted,

SHANKS & HERBERT

By: 
Joseph G. Contrera
Reg. No. 44,628

Date: 4/1/02

TransPotomac Plaza
1033 N. Fairfax Street
Suite 306
Alexandria, VA 22314



0420

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Yan, et al.

Art Unit: To Be Assigned

Serial No.: 09/997,240

Examiner: To Be Assigned

Filed: November 30, 2001

Atty. Docket: 0249-0001US

For: Isolated Homozygous Stem Cells,
Differentiated Cells Derived Therefrom,
And Materials And Methods For Making
And Using Same

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on the accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ 2. The Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ c. Attached is our check no. ____ in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicants hereby petition that the Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$130.00 in payment of the fee under 37 C.F.R. § 1.17(i)(1).
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).


- ☐b. I hereby certify that no item of information on this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- ☐8. Copies of the documents were cited by or submitted to the Office in Application No. _____, filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. **50-0622**.

Respectfully submitted,

SHANKS & HERBERT

By: 
Joseph G. Contrera
Reg. No. 44,628

Date: 1/22/02

TransPotomac Plaza
1033 N. Fairfax Street
Suite 306
Alexandria, VA 22314
703-683-3600